Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
17:20:58 EDT Mon 14 Jul 2025
Enter Symbol
or Name
USA
CA



Q:NBIX - NEUROCRINE BIOSCIENCES INC - https://WWW.NEUROCRINE.COM
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
NBIX - Q0.6132.52·137.701.2135.13+1.671.3613.181,96510,594132.33  135.45  131.75157.9799  84.2316:27:2516:3515 min RT 2¢

Recent Trades - Last 10 of 10594
Time ETExPriceChangeVolume
16:27:25Q135.131.67178
16:04:15Q135.131.671
16:04:15Q135.131.671
16:04:13Q135.131.671
16:04:12Q135.131.671
16:04:08Q135.131.671
16:04:07Q135.131.671
16:03:07Q135.131.6752
16:01:49Q135.131.67464
16:01:33Q135.131.6713

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-14 16:35U:NBIXNews ReleaseNeurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst(TM) Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society's Annual Meeting
2025-07-14 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents One-Year Data Showing Sustained Efficacy of CRENESSITY(TM) (crinecerfont) in Adult Patients, at ENDO 2025
2025-07-09 16:01U:NBIXNews ReleaseNeurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2025 Financial Results
2025-06-30 16:05U:NBIXNews ReleaseNeurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-01435, a Long-Acting Corticotropin-Releasing Factor Type 1 Receptor Antagonist
2025-06-27 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT(TM)-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA(TM) (valbenazine) Capsules for Huntington's Disease Chorea
2025-06-20 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA(TM) (valbenazine) Capsules in Older Adults with Tardive Dyskinesia
2025-06-09 16:05U:NBIXNews ReleaseNeurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
2025-06-02 08:30U:NBIXNews ReleaseNeurocrine Biosciences Presents Patient-Reported Outcomes from KINECT-PRO(TM) Study Demonstrating INGREZZA(TM) (valbenazine) Capsules Improved Functionality and Quality of Life in Patients with Tardive Dyskinesia
2025-05-30 16:30U:NBIXNews ReleaseFate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors
2025-05-28 16:05U:NBIXNews ReleaseNeurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025
2025-05-16 08:30U:NBIXNews ReleaseNeurocrine Biosciences to Present Wide-Ranging One-Year Data from Phase 3 CAHtalyst(TM) Pediatric Study at Pediatric Endocrine Society 2025 Annual Meeting
2025-05-16 08:25U:NBIXNews ReleaseNeurocrine Biosciences Presents Data Adding to the Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients with Tardive Dyskinesia
2025-05-15 16:05U:NBIXNews ReleaseNeurocrine Biosciences Presents Data on Improvements in Physiologic Glucocorticoid Dosing and Select Reproductive Hormones in Patients with Classic Congenital Adrenal Hyperplasia Taking CRENESSITY(TM) (crinecerfont)
2025-05-14 16:05U:NBIXNews ReleaseNeurocrine Biosciences Presents Findings Contributing to the Growing Body of Evidence on the Impact of High-Dose Glucocorticoids on Clinical Outcomes in Congenital Adrenal Hyperplasia
2025-05-08 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces New Results from Exploratory Analyses of the Phase 3 CAHtalyst(TM) Pediatric Study Demonstrating CRENESSITY(TM) Reduces Glucocorticoid Dosing While Maintaining or Improving Androstenedione Across Patient Subgroups
2025-05-06 16:01U:NBIXNews ReleaseNeurocrine Biosciences to Present at Upcoming Investor Conferences in May
2025-05-06 08:30U:NBIXNews ReleaseNeurocrine Biosciences and Carnie Wilson Team Up to Launch ConnectING with Carnie(TM) Awareness Campaign for People with Tardive Dyskinesia
2025-05-05 16:01U:NBIXNews ReleaseNeurocrine Biosciences Reports First Quarter 2025 Financial Results and Reaffirms 2025 Financial Guidance
2025-05-05 08:30U:NBIXNews ReleaseNeurocrine Biosciences Announces New Survey Revealing Need for Routine Screening and Earlier Diagnosis for People Living with Tardive Dyskinesia
2025-04-30 08:00U:NBIXNews ReleaseNeurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia